Becton Dickinson Total Current Liabilities 2010-2024 | BDX
Becton Dickinson total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
- Becton Dickinson total current liabilities for the quarter ending September 30, 2024 were $6.605B, a 3.97% decline year-over-year.
- Becton Dickinson total current liabilities for 2023 were $6.641B, a 14.98% decline from 2022.
- Becton Dickinson total current liabilities for 2022 were $7.811B, a 17.88% increase from 2021.
- Becton Dickinson total current liabilities for 2021 were $6.626B, a 13.54% increase from 2020.
Becton Dickinson Annual Total Current Liabilities
(Millions of US $) |
| 2023 |
$6,641 |
| 2022 |
$7,811 |
| 2021 |
$6,626 |
| 2020 |
$5,836 |
| 2019 |
$5,655 |
| 2018 |
$7,216 |
| 2017 |
$3,342 |
| 2016 |
$4,400 |
| 2015 |
$4,381 |
| 2014 |
$2,235 |
| 2013 |
$2,130 |
| 2012 |
$1,978 |
| 2011 |
$1,823 |
| 2010 |
$1,672 |
| 2009 |
$1,777 |
Becton Dickinson Quarterly Total Current Liabilities
(Millions of US $) |
| 2024-06-30 |
$6,605 |
| 2024-03-31 |
$7,327 |
| 2023-12-31 |
$7,540 |
| 2023-09-30 |
$6,641 |
| 2023-06-30 |
$6,878 |
| 2023-03-31 |
$7,304 |
| 2022-12-31 |
$7,625 |
| 2022-09-30 |
$7,811 |
| 2022-06-30 |
$7,080 |
| 2022-03-31 |
$6,657 |
| 2021-12-31 |
$6,735 |
| 2021-09-30 |
$6,626 |
| 2021-06-30 |
$7,749 |
| 2021-03-31 |
$5,376 |
| 2020-12-31 |
$7,021 |
| 2020-09-30 |
$5,836 |
| 2020-06-30 |
$6,067 |
| 2020-03-31 |
$8,755 |
| 2019-12-31 |
$6,726 |
| 2019-09-30 |
$5,655 |
| 2019-06-30 |
$6,237 |
| 2019-03-31 |
$7,108 |
| 2018-12-31 |
$7,145 |
| 2018-09-30 |
$7,216 |
| 2018-06-30 |
$6,106 |
| 2018-03-31 |
$4,426 |
| 2017-12-31 |
$4,895 |
| 2017-09-30 |
$3,342 |
| 2017-06-30 |
$3,273 |
| 2017-03-31 |
$4,018 |
| 2016-12-31 |
$4,570 |
| 2016-09-30 |
$4,400 |
| 2016-06-30 |
$4,219 |
| 2016-03-31 |
$4,380 |
| 2015-12-31 |
$4,529 |
| 2015-09-30 |
$4,381 |
| 2015-06-30 |
$4,517 |
| 2015-03-31 |
$4,497 |
| 2014-12-31 |
$2,081 |
| 2014-09-30 |
$2,235 |
| 2014-06-30 |
$2,093 |
| 2014-03-31 |
$2,016 |
| 2013-12-31 |
$1,997 |
| 2013-09-30 |
$2,130 |
| 2013-06-30 |
$1,693 |
| 2013-03-31 |
$1,878 |
| 2012-12-31 |
$2,004 |
| 2012-09-30 |
$1,978 |
| 2012-06-30 |
$1,890 |
| 2012-03-31 |
$1,621 |
| 2011-12-31 |
$1,606 |
| 2011-09-30 |
$1,823 |
| 2011-06-30 |
$1,658 |
| 2011-03-31 |
$1,579 |
| 2010-12-31 |
$1,612 |
| 2010-09-30 |
$1,672 |
| 2010-06-30 |
$1,531 |
| 2010-03-31 |
$1,467 |
| 2009-12-31 |
$1,539 |
| 2009-09-30 |
$1,777 |
| 2009-06-30 |
$1,646 |
| 2009-03-31 |
$1,511 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$66.954B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
